Invest in a pioneering diagnostics company
Invest from £12,000
EIS Approved | 30% Tax Relief | No CGT on Exit
And discover how you can help reshape the future of medical diagnostics.
Inside the Factsheet You Will Find:
- Message from the CEO
- The Problem & Solution
- EIS Statistics & Our Offer
- Management Team Profile
- Enterprise Investment Scheme Guide
- EIS Tax Relief Information
Download Your Free Factsheet Now
Minimum Investment £12,000
About Us
Imagine a world where the fear and uncertainty of breast cancer diagnosis are significantly reduced – a world where invasive biopsies and the anxiety of waiting are replaced with a simple, precise, and timely blood test. This is the world Frontier Diagnostics is creating.
The Urgent Need
Every year, millions are touched by the shadow of breast cancer. Traditional diagnostic methods are not just invasive; they often miss early detection opportunities and are blind to the unique nature of each patient's cancer.
The Frontier Revolution
Frontier Diagnostics stands at the forefront of cancer diagnostics with our advanced liquid biopsy. Our tests detect and analyse Circulating Tumour Cells, heralding a new era of personalised medicine in oncology. With our approach, we can spot signs of cancer up to 12 months earlier than conventional methods and tailor treatment strategies to each individual’s needs.
Unmatched Expertise
Under the leadership of our CEO Dr. Martin Burrow, a biochemist with over 30 years of experience, our team has spent a decade perfecting our methods. Dr. Burrow's work has laid the foundation for a methodology that is not just innovative, but proven, reliable, and ready to scale.
Growth and Vision
Our vision for expansion is clear and within reach. We will enhance our facilities, embrace AI technology, and launch an online platform for seamless patient-clinician interaction. By 2028, we aim to be conducting over 1,300 tests per week, becoming a market leader in cancer diagnostics.
Investment with Incentives
We offer more than just the promise of growth; we provide a tangible opportunity. Investing in Frontier Diagnostics means investing in a company that's post-money valuation and ready for rapid growth. Our projected ROI stands at an impressive 10X+, bolstered by the tax benefits of the EIS.*
And discover how you can help reshape the future of medical diagnostics.
*Projected returns, such as "10X+ ROI," are targets only and not guarantees, as past performance and forecasts are not reliable indicators of future results; achieving returns depends on numerous factors and carries substantial risk, and capital is at risk, while tax treatment depends on individual circumstances and may change, with EIS eligibility contingent on the company's continued qualifying status, so independent tax advice should be sought.
Why Invest with Frontier Diagnostics?
Cutting-Edge Diagnostics
Our advanced liquid biopsy methods are leading the way in precision oncology diagnostics.
Thriving Market Potential
Capitalising on the increasing demand for transparent and personalised healthcare.
Impactful Healthcare
Championing early cancer detection and ongoing monitoring for improved patient outcomes.
Expert Leadership Team
Guided by forward-thinking executives and backed by a seasoned medical advisory panel with a track record of achievements in biotechnology and diagnostics.
Generous Tax Benefits
Benefit from the generous tax reliefs offered under the HMRC Approved Enterprise Investment Scheme.
Maximise your Investment with EIS Tax Savings
30% Income Tax Relief
Investors benefit from a 30% tax relief on the total amount invested, capped at £1million per tax year.
Tax-Free
Growth
Any profits realised from an EIS investment are exempt from capital gains tax.
Capital Gains Reinvestment Relief
Offset capital gains from other investments when you reinvest in EIS-eligible companies.
Inheritance Tax Relief
Shares held in EIS-qualifying investments are exempt from inheritance tax.
45% Loss Relief
If you make a loss on an EIS investment, you can offset up to 45% of the loss against your income tax liability.
And discover how you can help reshape the future of medical diagnostics.
*Tax treatment depends on individual circumstances and may be subject to change in the future. EIS eligibility depends on the company maintaining its qualifying status. Seek independent tax advice.
Get our Factsheet Now
Registered Address: First Floor 690 Great West Road, Osterley Village, Isleworth, England, TW7 4PU
Risk Warning: Investing in Frontier Diagnostics carries significant risks and your capital is at risk; this website is for informational purposes only, directed at UK Sophisticated Investors or High Net Worth Individuals who must self-certify before receiving our Information Memorandum; projections are forward-looking, based on current assumptions, not guarantees, and actual results may differ materially; claims about our diagnostic technology are based on internal research and ongoing validation, and the technology remains under development and pending regulatory approval; information reflects current understanding and does not constitute investment or tax advice — consult independent advisors.
Frontier Diagnostics Ltd, First Floor, 690 Great West Road, Osterley Village, Isleworth, England, TW7 4PU, registered in England and Wales, No. 14416890.
Copyright © Frontier Diagnostics Ltd. 2025.